<DOC>
	<DOCNO>NCT02616744</DOCNO>
	<brief_summary>A single -- blind , randomize , placebo -- control phase II study evaluate impact oral bisphosphonate treatment bone mineral density osteopenic woman receive aromatase inhibitor adjuvant treatment .</brief_summary>
	<brief_title>Study Oral Bisphosphonate Osteopenic Women Treated With Adjuvant Aromatase Inhibitors</brief_title>
	<detailed_description>Aromatase inhibitor ( AIs ) adjuvant treatment choice postmenopausal woman early , hormone receptor-positive breast cancer ( BC ) , produce improved survival rate compare tamoxifen . Progressive bone loss subsequent fracture associate adjuvant AIs , administer either alone sequentially tamoxifen postmenopausal woman early BC . Recent finding National Surgical Adjuvant Breast Bowel Project ( NSABP ) B-34 also suggest bisphosphonates might anticancer benefit old postmenopausal woman . `` BONADIUV '' trial single-blind , randomize , placebo-controlled study design evaluate impact bisphosphonate treatment bone mineral density ( BMD ) woman take AIs . Patients undergo baseline BMD result osteopenic ( lumbar spine and/or trochanter -1 &lt; T-score &lt; 2.5 ) , randomize 1:1 ratio receive either placebo oral ibandronate . All patient receive oral supplementation calcium Vitamin D3 , daily two year . Study duration 2 year , plan six-months evaluation . A total 72 patient per arm treatment need obtain 85 % statistical power order detect 2 % BMD mean difference two arm . Considering 15 % dropout , around 82 patient per arm plan enrol .</detailed_description>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Diagnosis hormonereceptor positive early breast cancer Menopausal status Age &lt; 75 year Written inform consent Premenopausal status time randomization Comorbidities increase risk osteoporosis ( primary hyperparathyroidism , hyperthyroidism , rheumatoid arthritis ) BMI &lt; 18 Chronic use steroid Use bisphosphonates time randomization Psychiatric disorder</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>aromatase inhibitor</keyword>
	<keyword>breast cancer</keyword>
	<keyword>bone mineral density</keyword>
</DOC>